Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311883 · ClinicalTrials.gov registry record · Phase 1
Hydroxychloroquine in Cystic Fibrosis
A Phase 1 study of Cystic Fibrosis, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00311883 is a Phase 1 study of Cystic Fibrosis that has completed, run by Vanderbilt University. The registered enrollment target is 20 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00311883, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis before and after a 4 week course of oral hydroxychloroquine.
Conditions Studied
Interventions
- DRUG hydroxychloroquine
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311883
The ClinicalTrials.gov registry entry for NCT00311883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which hydroxychloroquine is the first listed.
NCT00311883 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00311883 about?
NCT00311883 is a clinical study titled "Hydroxychloroquine in Cystic Fibrosis". Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis before and after a 4 week course of oral hydroxychloroquine.
What is the current status of trial NCT00311883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-03. Estimated completion is 2007-12.
What conditions does trial NCT00311883 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT00311883?
The interventions under investigation include: hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT00311883?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00311883 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.